gut microbiota

BiomeBank announces world first regulatory approval for donor derived microbiome drug

Formal approval of BiomeBank’s first-generation donor derived microbiome-based therapy product, BIOMICTRA registered in the Australian Register of Therapeutic Goods

L. rhamnosus GG increases Bifidobacteria and reduces inflammation in children with cystic fibrosis, study says

A supplement of LGG would seem to favour the proliferation of Bifidobacterium and the improvement of clinical and immunological response to childhood cystic fibrosis.

Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx

Healthy, diabetic, and obese people compared on diet and lifestyle using innovative technologies and multi-omics analysis

New study demonstrates the positive outcomes of FMT in NAFLD patients

Faecal microbiota transplant appears to effectively improve both clinical parameters and bacterial balance in the liver, especially in thin individuals.

World-first microbiome-focused study may offer new hope to rheumatoid arthritis sufferers via improved gut health

Servatus are hopeful this study will eventuate into real benefits to sufferers of rheumatoid arthritis

New study supports link between gut bacteria and multiple sclerosis

The findings of a new research shed light on the mechanisms by which gut bacteria influence the development and progression of multiple sclerosis.

OptiBiotix launches highly effective low dose prebiotic to stimulate targeted gut microbial growth

René Kamminga, CEO of OptiBiotix: “OptiXOS is unlike any prebiotic fibre commercially available in Europe today".

High levels of antibodies against specific gut bacteria may be linked to chronic fatigue

The findings of a new research suggest that combining Lachnospiraceae antibody screening with blood tests could improve the diagnosis of ME/CFS.

BioAro launches its genomics and microbiome services, bringing ease of access and the most comprehensive health analysis of DNA to the North American public before its global expansion

BioAro is a biotechnology company redefining healthcare through genetic sequencing, AI development and blockchain technologies.

High-sugar diet could disrupt microbiota, increase odds of obesity and diabetes

The findings of a new study suggest that the interplay between diet, microbiota and intestinal immunity regulates obesity, diabetes and other metabolic conditions.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top